40

Volasertib

40 Publications Verification

Cat. No.: HY-12137

CAS No.: 755038-65-4

Purity: 99.87%

Synonyms: BI 6727

Target:

Polo-like Kinase (PLK) Apoptosis

Research Areas:

Cancer

Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[2].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

40

Volasertib trihydrochloride

40 Publications Verification

Cat. No.: HY-12137A

CAS No.: 946161-17-7

Synonyms: BI 6727 trihydrochloride

Target:

Polo-like Kinase (PLK) Apoptosis

Research Areas:

Cancer

Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[2].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

ON1231320

4 Cited Publications

Cat. No.: HY-100789

CAS No.: 1312471-39-8

Purity: 99.90%

Target:

Apoptosis Polo-like Kinase (PLK) Mitosis

Research Areas:

Cancer

ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC₅₀ of 0.31 μM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity ^[2].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Ro3280

4 Cited Publications

Cat. No.: HY-15161

CAS No.: 1062243-51-9

Purity: 99.46%

Target:

Polo-like Kinase (PLK)

Research Areas:

Cancer

Ro3280 is a potent, highly selective inhibitor of PLK1 with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

TC-S 7005

4 Cited Publications

Cat. No.: HY-108597

CAS No.: 1082739-92-1

Purity: 99.68%

Target:

Polo-like Kinase (PLK)

Research Areas:

Cardiovascular Disease Inflammation/Immunology

TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

TAK-960

2 Cited Publications

Cat. No.: HY-15160

CAS No.: 1137868-52-0

Purity: 99.75%

Target:

Polo-like Kinase (PLK)

Research Areas:

Cancer

TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

TAK-960 dihydrochloride

2 Cited Publications

Cat. No.: HY-15160B

Purity: 99.19%

Target:

Polo-like Kinase (PLK)

Research Areas:

Cancer

TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

CCB02

1 Cited Publications

Cat. No.: HY-114302

CAS No.: 2100864-57-9

Purity: 99.89%

Target:

Microtubule/Tubulin

Research Areas:

Cancer

CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

SBE13 Hydrochloride

Cat. No.: HY-15158

CAS No.: 1052532-15-6

Purity: 99.66%

Target:

Polo-like Kinase (PLK) Autophagy Apoptosis

Research Areas:

Cancer

SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

Compare

loading...